NCT04575766 - A Study of FT-7051 in Men With MCRPC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

November 8, 2022

Study Completion Date

November 15, 2022

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

FT-7051

"Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level."

Trial Locations (8)

10029

Icahn School of Medicine at Mt. Sinai, New York

21201

University of Maryland, Greenebaum Cancer Center, Baltimore

27710

Duke University Health System, Durham

29572

Carolina Urologic Research Center, Myrtle Beach

60611

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

80045

University of Colorado Health, Aurora

85258

HonorHealth, Scottsdale